Inquiry Basket
MC-Val-Cit-PAB-duocarmycin is a drug-linker conjugate for ADC with potent antitumor activity by using duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-00633 | -- | $-- | Inquiry |
MC-Val-Cit-PAB-duocarmycin is a powerful targeted drug conjugate that combines the potent DNA-intercalating agent duocarmycin with a selective peptide linker. Duocarmycin is known for its ability to bind to DNA and induce strand breaks, which disrupts DNA replication and leads to cell death, particularly in rapidly dividing cancer cells. The conjugation of duocarmycin with the MC-Val-Cit-PAB linker enables the precise delivery of this cytotoxic agent directly to tumor cells, significantly improving the therapeutic index by concentrating the drug at the tumor site while minimizing systemic toxicity.
One of the primary applications of MC-Val-Cit-PAB-duocarmycin is in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. The peptide linker allows for selective targeting of cancer cells that overexpress specific cell surface markers, ensuring that duocarmycin is delivered specifically to tumor cells. This targeted approach enhances the effectiveness of duocarmycin by ensuring it is concentrated where it is needed most, while reducing damage to healthy tissues. This makes MC-Val-Cit-PAB-duocarmycin an attractive candidate for treating cancers that are resistant to conventional chemotherapies.
In addition to its use in ADCs, MC-Val-Cit-PAB-duocarmycin offers an innovative strategy to overcome drug resistance in cancer therapy. Many tumors develop resistance to traditional chemotherapeutic agents due to the inability of drugs to specifically target cancer cells. By using a targeted delivery system, MC-Val-Cit-PAB-duocarmycin bypasses some of the common resistance mechanisms, ensuring that the cytotoxic agent is delivered directly to the cancer cells. This targeted mechanism may help improve the efficacy of treatment, even in cases where resistance to other therapies has developed.
MC-Val-Cit-PAB-duocarmycin also demonstrates the potential to enhance the pharmacokinetics of duocarmycin. Traditional chemotherapy with duocarmycin and other DNA-damaging agents often suffers from poor bioavailability, short half-lives, and high systemic toxicity. The MC-Val-Cit-PAB linker improves the solubility and stability of duocarmycin, allowing for more efficient delivery to the tumor. This controlled release system ensures that the drug is active longer and reaches the cancerous tissue with greater precision, leading to enhanced therapeutic outcomes with fewer side effects.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
